Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-Napathalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof

Abstract

DNT-Oxal crystalline forms and processes for making DNT-Oxal crystalline forms are provided.

1 . A crystalline form of DNT-Oxal, characterized by an X-ray powder diffraction pattern having peaks at about 6.7, 15.5, 17.6, 20.1 and 23.4 degrees two-theta ±0.2 degrees two-theta. 
   
   
       2 - 13 . (canceled) 
   
   
       14 . A crystal form of DNT-Oxal, characterized by an X-ray powder diffraction pattern having peaks at about:
 6.2, 18.7, 19.8, 21.3 and 24.9 degrees two-theta, ±0.2 degrees two-theta;   6.7, 12.2, 15.6, 20.7 and 22.4 degrees two-theta, ±0.2 degrees two-theta;   6.6, 13.2, 19.8 and 23.1 degrees two-theta, ±0.2 degrees two-theta;   7.1 and 21.1 degrees two-theta, ±0.2 degrees two-theta;   6.9, 15.5, 20.9, and 23.2 degrees two-theta ±0.2 degrees two-theta;   6.6, 15.2, 20.0, 22.8 and 26.1 degrees two-theta ±0.2 degrees two-theta; or   6.4, 19.0, 20.1, 21.6 and 25.5 degrees two-theta ±0.2 degrees two-theta.   
   
   
       15 . (canceled) 
   
   
       16 . A pharmaceutically acceptable salt of duloxetine, prepared by obtaining a DNT-Oxal crystalline form of  claim 1  or  claim 14 , and converting the DNT-Oxal crystalline form to a pharmaceutically acceptable salt of duloxetine. 
   
   
       17 . The pharmaceutically acceptable salt of  claim 16 , wherein the DNT-Oxal crystalline form is converted to duloxetine hydrochloride.